Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

PCSK9 Inhibitor Market Outlook from 2024 to 2034

Exhibiting a y-o-y growth of 21.5%, the global PCSK9 inhibitor market size is estimated to reach US$ 2,733.7 million in 2024. It will likely expand at a CAGR of 18.7% during the forecast period, with total sales of PCSK9 inhibitors reaching US$ 15,140.3 million by 2034.

The evolocumab segment is projected to dominate the PCSK9 inhibitor industry, holding a value share of 71.3% in 2024. However, sales of inclisiran are likely to expand at a staggering CAGR of 31.3% during the assessment period.

Attributes Key Insights
Base Value (2023) US$ 2,250.4 million
Estimated PCSK9 Inhibitor Market Value (2024) US$ 2,733.7 million
Projected PCSK9 Inhibitor Market Revenue (2034) US$ 15,140.3 million
Value CAGR (2024 to 2034) 18.7%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Key Factors Fueling Growth of the PCSK9 Inhibitor Market

  • Rising prevalence of cardiovascular diseases globally
  • Growing aging population
  • High efficiency and effectiveness of PCSK9 inhibitors
  • Increasing spending on cholesterol management medications
  • Escalating need for PCSK9 inhibitor therapy and atherosclerosis treatment
  • Expanding pipeline of PCSK9 inhibitors
  • Limited efficacy of statins and other cholesterol-lowering drugs
  • Increasing healthcare awareness and growing need for advanced hypercholesterolemia treatments
  • Reduction in PCSK9 inhibitor prices

Opportunities in the PCSK9 Inhibitor Market

  • Expanding indications through ongoing research
  • Potential advancements in personalized medicine for more targeted treatment strategies
  • Increasing cases of high cholesterol
  • Growing awareness about the high efficacy of PCSK9 inhibitors
  • Introduction of favorable reimbursement policies, especially across developed and developing nations
  • Ongoing trials demonstrating the efficacy of PCSK9 inhibitors in reducing LDL cholesterol levels and improving cardiovascular outcomes
  • Development of biosimilar versions of PCSK9 inhibitors
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Latest PCSK9 Inhibitor Market Trends

Rapid Shift toward Personalized Medicine is a Key Market-shaping Trend

  • Shift toward personalized medicine
  • Growing interest in preventive healthcare
  • Development of new formulations like longer-acting drugs and subcutaneous injections
  • Increasing research on combination therapies with other LDL cholesterol-lowering drugs
  • New product launches, along with continuous approvals from regulatory bodies like the FDA and EMA

The emergence of PCSK9 inhibitors has completely revolutionized how people manage high cholesterol, also known as bad LDL cholesterol. Owing to their safe and highly effective nature, they are witnessing higher demand globally, and the trend will likely continue through 2034.

Research has shown that PCSK9 inhibitors can reduce LDL cholesterol by 50% to 60% on average compared to statins. They work by targeting the PCSK9 protein, which plays a key role in regulating LSL levels in the blood. These novel drugs can also reduce the risk of CVDs.

The rising incidence of cardiovascular diseases is acting as a catalyst fueling demand for PCSK9 inhibitors. Similarly, the growing geriatric population will likely create growth opportunities for PCSK9 inhibitor manufacturers.

Cardiovascular diseases, such as stroke and heart attacks, continue to be a leading cause of morbidity and mortality globally. As per the World Health Organization (WHO), around 17.9 million people die from CVDs annually. This is expected to uplift the demand for cholesterol-lowering therapies like PCSK9 inhibitors.

One significant modifiable risk factor for myocardial infarction, stroke, and cardiovascular disease-related death is the amount of low-density lipoprotein cholesterol (LDL-C). To counter this, people consume medications like PCSK9 inhibitors, thereby fueling their sales.

PCSK9 inhibitors have proven to be remarkably effective in reducing LDL-C, especially in people who are intolerant to statins or have a family history of high cholesterol. Thus, growing cases of high cholesterol will likely propel sales of PCSK9 inhibitors through 2034.

Research and development efforts to find novel therapeutic interventions have surged in response to the growing burden of cardiovascular diseases (CVDs). This is paving the way for the development and approval of new PCSK9 inhibitors.

Historical Performance Vs. Future PCSK9 Inhibitor Demand Analysis

The global market for PCSK9 inhibitors recorded a stupendous CAGR of 21.3% from 2019 to 2023. It reached a valuation of US$ 2,250.4 million at the end of 2023. In the forecast period, PCSK9 inhibitor sales are set to soar at 18.7% CAGR.

The remarkable expansion of the PCSK9 inhibitor market can be attributed mostly to the clinical efficacy and safety of these drugs. These novel biopharmaceuticals have revolutionized the treatment of hypercholesterolemia and cardiovascular disorders by specifically targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).

A thorough examination of the clinical environment demonstrates how PCSK9 inhibitors' safety and efficacy are propelling their broad use and aiding in the market's growth. The principal factor behind the growing market for PCSK9 inhibitor drugs is the medications' exceptional clinical efficacy.

Low-density lipoprotein cholesterol (LDL-C) levels are significantly lowered by PCSK9 inhibitors, either taken as monotherapy or in combination with statins, according to numerous clinical trials. Known as "bad cholesterol," low-density lipoprotein (LDL-C) is a major cause of atherosclerosis and coronary heart disease.

The market for PCSK9 inhibitors has grown significantly in recent years due to the growing regulatory backing and approval for these novel cholesterol-lowering medications. The regulatory environment significantly shapes the pharmaceutical sector, impacting drug research, market accessibility, and patient care.

The rise of the PCSK9 inhibitor market has been greatly aided by the regulatory agencies' increasing recognition and endorsement of these drugs globally. Growing awareness of the higher effectiveness of these medications will likely fuel their sales through 2034.

The regulatory approval of PCSK9 inhibitors by major organizations like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) was a significant turning point in the development of these drugs. With these approvals, the treatment of hypercholesterolemia and atherosclerotic cardiovascular disorders underwent a paradigm change.

Patient empowerment has emerged as a major concern for awareness initiatives. Patient advocacy groups and cardiovascular health organizations are essential in informing people about the advantages of PCSK9 inhibitor drugs. These programs help people feel more empowered and knowledgeable, which in turn influences treatment decisions by facilitating educated conversations between patients and their healthcare professionals.

The rising demand for PCSK9 inhibitors is indicative of the increase in health awareness. Acknowledging the expanding market potential, pharmaceutical companies are allocating resources toward research and development to improve current formulations and create novel PCSK9 inhibitor drugs. The market for PCSK9 inhibitors is growing at a rapid pace thanks to this cycle of awareness, market response, and innovation.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Insights into Factors Propelling PCSK9 Inhibitor Demand

  • Rising Prevalence of Familial Hypercholesterolemia

Meeting the unmet requirements of individuals with hypercholesterolemia that are difficult to treat is one of the major potential growth areas in the PCSK9 inhibitor market. An important cardiovascular risk is posed by familial hypercholesterolemia, a genetic condition that results in abnormally high cholesterol levels.

PCSK9 inhibitors function by blocking PCSK9, a protein that controls the quantity of LDL receptors on the surface of hepatic cells, providing a tailored treatment strategy. By doing this, these inhibitors improve the liver's capacity to eliminate LDL-C from the blood. They provide a potentially effective treatment option for individuals whose conventional medications are unable to sufficiently regulate their cholesterol levels.

Targeting the underlying cause of hypercholesterolemia, these medications improve the liver's capacity to eliminate LDL-C from the bloodstream by blocking PCSK9 activity. PCSK9 inhibitors' adaptability and ease of use help individuals with hard-to-treat hypercholesterolemia get the care they need. By meeting the challenges and overcoming them, manufacturers are creating opportunities for the PCSK9 inhibitor market to grow in the coming years.

  • Growing Interest in Precision Medicine

The PCSK9 inhibitor market is expected to grow rapidly due to the changing nature of cardiovascular care and the growing emphasis on individualized therapy. Demand for focused and customized strategies is rising as medical professionals become more aware of the variation in individual patients' responses to lipid-lowering treatments.

PCSK9 inhibitors are useful tools for customizing treatment plans based on specific patient profiles. This is because of their distinct mechanism of action and capacity to achieve significant LDL-C reductions.

PCSK9 inhibitors are an outstanding example of precision medicine in cardiovascular treatment. These inhibitors address a significant component of cardiovascular risk by modulating the levels of low-density lipoprotein cholesterol (LDL-C) and targeting the PCSK9 protein.

Overview of Factors Impeding the PCSK9 Inhibitor Market Growth

  • High Cost of PCSK9 Inhibitors and Lack of Reimbursement Policies

The reimbursement landscape is a major factor in deciding which PCSK9 medications are accessible. There's a chance that a lot of healthcare systems and insurers won't pay for these medications in full because of financial limitations and the necessity to put cost-effectiveness first.

In order to shape payment rules, negotiations between healthcare payers and pharmaceutical producers are essential. The complex dynamics of these talks frequently lead to a trade-off between the clinical advantages of PCSK9 inhibitors and the stakeholders' financial interests in healthcare.

The high cost of these biopharmaceuticals is a key factor limiting the growth of the PCSK9 inhibitor market. Significant research investments and technological breakthroughs are needed to develop and produce PCSK9 inhibitors, which is an expensive process.

The problem comes when healthcare payers, both public and private, face financial restraints and must weigh the clinical advantages of PCSK9 inhibitors against their viability from an economic standpoint. The hefty cost of PCSK9 inhibitors frequently causes insurance companies to hesitate to offer full coverage.

The hesitation derives from the need to weigh the financial viability of healthcare systems against the demand for patient access to cutting-edge treatments. Payers must decide if the additional therapeutic benefits provided by PCSK9 inhibitors outweigh the premium cost when compared to other cholesterol-lowering medications, such as statins, which can be a difficult decision to make.

The availability of healthcare resources, such as trained doctors and specialized facilities, may vary significantly between various locations or nations. This may lead to unequal access to therapies for cardiovascular diseases such as primary hyperlipidemia and familial hypercholesterolemia.

The unequal access to therapies makes it difficult for patients in underserved or isolated locations to receive rapid, effective care. Treatments for cardiovascular diseases can be expensive, specifically the more sophisticated ones that include intravitreal injections. This can limit market expansion through 2034.

Population-level economic differences may result in financial barriers for some individuals, making it more difficult for them to afford the appropriate treatment. Patients may be discouraged from obtaining or completing therapy for PCSK9 inhibitors if it is out of their financial reach.

Comparative View of Adjacent PCSK9 Inhibitor Markets

The global market for PCSK9 inhibitors is likely to be impacted by the peer or tangential markets in the healthcare division. These include the PARP inhibitor market and the kinase inhibitor in the autoimmune disease industry. The report briefly analyzes drivers and trends in all these markets for a better understanding.

The global PCSK9 inhibitor industry is poised to expand more than the other related industries. This growth is expected to be propelled by the rising prevalence of high cholesterol & cardiovascular diseases, growing healthcare awareness, and continuous new product launches & approvals.

PCSK9 Inhibitor Market Analysis:

Attributes Global PCSK9 Inhibitor Market Forecast
CAGR (2024 to 2034) 18.7%
Growth Factor The increasing prevalence of hypercholesterolemia and cardiovascular diseases is expected to drive the growth of the PCSK9 inhibitor market.
Market Trend Improved pipelines and drug availability, growing demand for hyperlipidemia medication, and high efficacy of PCSK9 antagonists will further support market expansion through 2034.

PARP Inhibitor Market Analysis:

Attributes PARP Inhibitor Demand Outlook
CAGR (2024 to 2034) 11.2%
Growth Factor The rising incidence of cancer is expected to boost the PARP inhibitor market growth.
Market Trend A key trend observed in the market is the growing demand for advanced targeted therapy for treating chronic diseases like cancer.

Kinase Inhibitor in Autoimmune Disease Market Analysis:

Attributes Kinase Inhibitor in Autoimmune Disease Market Forecast
CAGR (2024 to 2034) 5.4%
Growth Factor The increasing prevalence of autoimmune diseases globally is expected to uplift the demand for kinase inhibitors.
Market Trend Rising investments in research and development will likely support market expansion through 2034.

Country-wise Insights

The table below highlights the growth projections of the top nations. The United States is expected to lead the global PCSK9 inhibitor industry throughout the forecast period. This can be attributed to rising cases of cardiovascular diseases, increasing awareness of familial hypercholesterolemia, and growing demand for novel LDL cholesterol-lowering drugs and cholesterol management medications.

Market Growth Outlook by Key Countries

Countries Value CAGR
United States 17.0%
Germany 13.4%
South Korea 26.2%
India 9.4%
Italy 21.0%

Rising Prevalence of Cardiovascular Diseases Fueling Demand in the United States

The United States dominates the global PCSK9 inhibitor industry, contributing a value share of 41.6% in 2023. Over the assessment period, demand for PCSK9 inhibitors in the United States is projected to increase at a CAGR of 17.0%. Some of the key drivers/trends include:

  • Increasing prevalence of cardiovascular diseases and high cholesterol
  • Shifting preference from traditional medications like statins towards PCSK9 inhibitors
  • Improved patient outcomes of PCSK9 inhibitors
  • Growing popularity of monoclonal antibody inhibitors in cholesterol management
  • Approval of PCSK9 inhibitors for broader patient populations with mixed dyslipidemia, atherosclerosis, and certain cancer types

The United States has a substantial burden of cardiovascular diseases (CVD), with a large population affected by conditions such as coronary artery disease, heart attacks, and strokes. Given the association between high cholesterol levels and cardiovascular risk, there is a considerable demand for effective cholesterol-lowering therapies like PCSK9 inhibitors.

The United States has a well-developed and advanced healthcare infrastructure with widespread access to medical care. This facilitates the diagnosis and management of cardiovascular risk factors, including high cholesterol levels, thereby fostering market growth.

The strong presence of leading PCSK9 inhibitor manufacturers is another key factor expected to improve the United States PCSK9 inhibitor market share. These top companies are launching new clinical trials to expand their portfolio of PCSK9 inhibitors.

South Korea to Create Ample Growth Opportunities for Manufacturers

South Korea is emerging as a highly lucrative market for PCSK9 inhibitor manufacturers, and the trend is expected to continue through 2034. It held a dominant revenue share of 57.9% in the East Asia PCSK9 inhibitor market in 2023.

Over the forecast period, South Korea's PCSK9 inhibitor industry is poised to advance at a staggering CAGR of 26.2%. It will likely total US$ 1,251.03 million in 2034, driven by factors like:

  • Aging population and rising cases of cardiovascular diseases (CVDs)
  • Rising healthcare awareness and spending
  • Supportive government policies and initiatives, along with expanding insurance coverage for CVD treatments, including PCSK9 inhibitor therapy
  • Increasing domestic research into PCSK9 inhibitors and their potential application
  • Growing demand for anti-atherosclerotic drugs

As the economy grows and the standard of living improves, there is a trend of increased healthcare spending in South Korea. This can lead to greater demand for various healthcare products, including pharmaceuticals like PCSK9 inhibitors.

South Korea has been an active participant in clinical trials and research collaborations. Pharmaceutical manufacturers may find opportunities to engage in partnerships with Korean research institutions and hospitals for clinical development. This will likely further boost the growth of Korea’s PCSK9 inhibitor market.

Increasing Government Initiatives Fostering Growth of India’s Market

India’s PCSK9 inhibitor market is anticipated to grow at a CAGR of 9.4% during the forecast period. The total market valuation in the nation will likely reach US$ 284.68 million in 2034. This can be attributed to a combination of factors, including:

  • Rising awareness about cardiovascular health and improved healthcare access
  • Increasing government initiatives to make drugs like PCSK9 inhibitors more affordable
  • Improved pipelines and drug availability
  • Growing incidence of hypercholesterolemia
  • High spending on cholesterol management medications
  • Expanding cardiovascular drug market

The expanding middle-class population in India is associated with improved affordability and increased spending on healthcare. This can potentially drive the demand for innovative and advanced pharmaceutical products, including PCSK9 inhibitors.

Government initiatives aimed at improving healthcare infrastructure, increasing access to healthcare services, and addressing non-communicable diseases may create an environment conducive to the adoption of advanced pharmaceuticals. This will positively impact sales of PCSK9 inhibitors across India.

Category-wise Insights

The section below shows the evolocumab segment dominating the PCSK9 inhibitor industry. It is projected to account for a revenue share of 71.3% in 2024. Based on modality, the fully humanized monoclonal antibodies segment will likely hold a market share of 93.3% in 2024.

By indication, the familial hyper cholesterolemia category is expected to lead the market, holding a value share of 42.5% in 2024. Based on sales channels, the hospitals segment is poised to expand at 13.2% CAGR, holding a market share of 40.9% in 2024.

Strong LDL-C Reduction Capability of Evolocumab Fueling its Adoption

Market Growth Outlook by Drug

Drug Value CAGR
Alirocumab 11.3%
Evolocumab 19.4%
Inclisiran 31.3%

Evolocumab remains the most favorable choice for patients with high cholesterol. As per the latest analysis, demand for evolocumab is projected to rise at 19.4% CAGR during the forecast period, totaling a valuation of US$ 9,272.36 million in 2034.

Evolocumab, sold under the brand name Repatha, is often considered the most effective PCSK9 inhibitor at lowering LDL-C levels. It has shown a slightly greater average reduction in LDL-C levels compared to other PCSK9 inhibitors, thereby fueling its adoption and demand.

  • Evolocumab, like other PCSK9 inhibitors, is known for its high efficacy in significantly lowering low-density lipoprotein cholesterol (LDL-C), a major risk factor for cardiovascular diseases. The ability to achieve substantial reductions in LDL-C levels is a crucial factor fueling the adoption of evolocumab.
  • Positive clinical trial results, demonstrating both the safety and efficacy of evolocumab in reducing LDL-C levels, also contribute to its leading position.
  • Clinical data supporting cardiovascular benefits have also been influential in establishing the drug's effectiveness. Evolocumab has a robust body of evidence indicating its ability to decrease adverse cardiovascular events like strokes and heart attacks.

Established Efficacy of Fully-humanized mAbs Making them Popular in the Market

Market Growth Outlook by Modality

Modality Value CAGR
Fully-humanized monoclonal antibodies 17.9%
siRNA 31.3%

Both small interfering RNA (siRNA) and fully humanized monoclonal antibodies (mAbs) are emerging classes of PCSK9 inhibitors with the tendency to revolutionize lipid-lowering therapy. Among these, fully humanized mAbs remain a popular category owing to their well-established efficacy and safety profiles.

The fully humanized monoclonal antibodies segment is anticipated to thrive at 17.9% CAGR during the forecast period. It will likely hold a value share of 93.3% in 2024.

  • Fully humanized monoclonal antibodies are designed to specifically target PCSK9 proteins, leading to a high degree of specificity in binding. This targeted approach allows for effective inhibition of PCSK9, resulting in a reduction of low-density lipoprotein cholesterol (LDL-C) levels.
  • mAbs have demonstrated positive clinical outcomes in reducing cardiovascular events, thereby fueling their adoption globally.
  • Fully humanized monoclonal antibodies generally exhibit consistent pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) across a diverse patient population. This predictability is advantageous in terms of dosing and treatment outcomes.

Familial Hyper Cholesterolemia Creating Lucrative Prospects for Companies

Market Growth Outlook by Key Indication

Indication Value CAGR
Primary Hyperlipidemia 20.7%
Familial Hyper Cholesterolemia 14.6%
Prevention of Other Cardiovascular Events 24.8%

Based on indication, the familial hyper cholesterolemia segment is set to account for a revenue share of 42.5% in 2024. Over the forecast period, the same segment will likely exhibit a CAGR of 14.6%. This is due to factors like

  • Growing prevalence of familial hypercholesterolemia
  • Rising need for effective medications like PCSK9 inhibitors to treat familial hypercholesterolemia

Familial hypercholesterolemia is often difficult to manage with traditional lipid-lowering therapies alone. PCSK9 inhibitors offer a targeted approach to lower LDL-C levels in these patients, addressing an unmet medical need for effective treatments.

Familial hypercholesterolemia can also affect children, and PCSK9 inhibitors have been studied and approved for use in pediatric populations. This expands the potential patient pool for PCSK9 inhibitors in addressing familial hypercholesterolemia.

Competitive Landscape

Clinical trials can serve as a powerful promotional strategy for a company, offering a multifaceted approach to showcasing its commitment to innovation, patient care, and scientific advancement. Securing approval from the U.S. Food and Drug Administration (FDA) is a significant achievement for any pharmaceutical or biopharmaceutical company.

Top manufacturers of PCSK9 inhibitors are heavily investing in research and development to explore novel treatment approaches for high cholesterol. For instance, they are exploring combination therapies with other cholesterol-lowering drugs to broaden the application of PCSK9 inhibitors and improve patient outcomes.

Recent Developments in the PCSK9 Inhibitor Market

  • In April 2021, Praluent (alirocumab) injection was approved by the Food and Drug Administration (FDA) for patients with homozygous familial hypercholesterolemia (HoFH).
  • In November 2023, LIB Therapeutics completed the global phase 3 LIBerate program of Lerodalcibep, a new third-generation PCSK9 inhibitor in development for cardiovascular diseases.
  • In August 2023, Merck initiated the Phase 3 clinical program for oral PCSK9 inhibitor candidate MK-0616. The oral PCSK9 inhibitor (MK-0616) is being evaluated for the treatment of adults with hypercholesterolemia.

Key Players in the PCSK9 Inhibitor Market Include

  • Novartis AG
  • Regeneron Pharmaceuticals, Inc. (Sanofi)
  • Amgen Inc.
  • Innovent
  • LIB Therapeutics, LLC
  • Shanghai Junshi Biosciences Co., Ltd
  • Merck & Co., Inc.
  • AstraZeneca

Key Market Segments Covered in PCSK9 Inhibitor Industry Research

By Drug:

  • Alirocumab
  • Evolocumab
  • Inclisiran
  • Tafolecimab

By Modality:

  • Fully-humanized monoclonal antibodies
  • siRNA

By Indication:

  • Primary Hyperlipidemia
  • Familial Hyper Cholesterolemia
  • Prevention of Other Cardiovascular Events

By Sales Channel:

  • Hospitals
  • Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Western Europe
  • Eastern Europe
  • Middle East & Africa

Frequently Asked Questions

What is the market size of PCSK9 inhibitors?

The global PCSK9 inhibitor market size is set to reach US$ 2,733.7 million in 2024.

What is the demand outlook for PCSK9 inhibitors?

Global PCSK9 inhibitor demand is poised to expand at 18.7% CAGR through 2034.

What is the projected market value for 2034?

The PCSK9 inhibitor market value is projected to total US$ 15,140.3 million by 2034.

What was the historical CAGR for the global market?

The global market recorded a CAGR of 21.3% from 2019 to 2023.

What is the sales forecast for the United States market?

Sales of PCSK9 inhibitors in the United States are projected to soar at 17.0% CAGR.

What is the growth projection of China market?

China is poised to witness a rapid CAGR of 23.3% from 2024 to 2034.

Are PCSK9 inhibitors available in India?

Yes, PCSK9 inhibitors are available in India.

Who are the manufacturers of PCSK9 inhibitors?

Novartis AG, Regeneron Pharmaceuticals, Inc. (Sanofi), Amgen Inc., and Innovent, among others.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Development/Innovation Trends

4. Value-Added Insights

    4.1. Drug Type Adoption / Usage Analysis (2024)

    4.2. List of Approved Products

    4.3. Key Disease Epidemiology

    4.4. Inclisiran Prescribing Information

    4.5. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia

    4.6. Pipeline Analysis

    4.7. Regulatory Landscape

    4.8. Porter’s Analysis

    4.9. PESTLE Analysis

    4.10. Reimbursement Scenario

    4.11. Value Chain Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global Healthcare Expenditure Outlook

        5.1.2. R&D funding By Region & Country

        5.1.3. Global Cholesterol-Lowering Drugs Market Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Cost of PCSK9 Inhibitor

        5.2.2. Advancement in Technology

        5.2.3. Rise in Cardiovascular Cases

        5.2.4. Availability of Products across Regions

        5.2.5. Products Under Clinical Trial

        5.2.6. Market Consolidation Activities

        5.2.7. Regulatory Landscape

        5.2.8. Healthcare Professionals Preferences And Awareness

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034

    6.1. Revenue Opportunity Analysis

    6.2. Historical Market Value (US$ million) Analysis, 2019 to 2023

    6.3. Current and Future Market Value (US$ million) Projections, 2024 to 2034

        6.3.1. Y-o-Y Growth Trend Analysis

        6.3.2. Absolute $ Opportunity Analysis

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ million) By Drug, 2019 to 2023

    7.3. Current and Future Market Size (US$ million) and Forecast By Drug, 2024 to 2034

        7.3.1. Alirocumab

        7.3.2. Evolocumab

        7.3.3. Inclisiran

        7.3.4. Tafolecimab

    7.4. Market Attractiveness Analysis By Drug

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Modality

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ million) By Modality, 2019 to 2023

    8.3. Current and Future Market Size (US$ million) and Forecast By Modality, 2024 to 2034

        8.3.1. Fully-humanized monoclonal antibodies

        8.3.2. siRNA

    8.4. Market Attractiveness Analysis By Modality

9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ million) By Indication, 2019 to 2023

    9.3. Current and Future Market Size (US$ million) and Forecast By Indication, 2024 to 2034

        9.3.1. Primary Hyperlipidemia

        9.3.2. Familial Hyper Cholesterolemia

        9.3.3. Prevention of Other Cardiovascular Events

    9.4. Market Attractiveness Analysis By Indication

10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sales Channel

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ million) By Sales Channel, 2019 to 2023

    10.3. Current and Future Market Size (US$ million) Analysis and Forecast By Sales Channel, 2024 to 2034

        10.3.1. Hospitals

        10.3.2. Specialty Clinics

        10.3.3. Retail Pharmacies

        10.3.4. Online Pharmacies

    10.4. Market Attractiveness Analysis By Sales Channel

11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ million) Trend Analysis by Region, 2019 to 2023

    11.3. Current and Future Market Size (US$ million) and Forecast by Region, 2024 to 2034

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. East Asia

        11.3.4. South Asia & Pacific

        11.3.5. Western Europe

        11.3.6. Eastern Europe

        11.3.7. Middle East & Africa

    11.4. Market Attractiveness Analysis by Region

12. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034

    12.1. Introduction

    12.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023

    12.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2024 to 2034

        12.3.1. By Country

            12.3.1.1. United States

            12.3.1.2. Canada

            12.3.1.3. Mexico

        12.3.2. By Drug

        12.3.3. By Modality

        12.3.4. By Indication

        12.3.5. By Sales Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug

        12.4.3. By Modality

        12.4.4. By Indication

        12.4.5. By Sales Channel

    12.5. Market Trends

    12.6. Drivers & Restraints Impact Analysis

    12.7. Country-Wise Analysis

        12.7.1. United States Market Analysis

            12.7.1.1. Introduction

            12.7.1.2. Market Analysis and Forecast by Market Taxonomy

                12.7.1.2.1. By Drug

                12.7.1.2.2. By Modality

                12.7.1.2.3. By Indication

                12.7.1.2.4. By Sales Channel

        12.7.2. Canada Market Analysis

            12.7.2.1. Introduction

            12.7.2.2. Market Analysis and Forecast by Market Taxonomy

                12.7.2.2.1. By Drug

                12.7.2.2.2. By Modality

                12.7.2.2.3. By Indication

                12.7.2.2.4. By Sales Channel

        12.7.3. Mexico Market Analysis

            12.7.3.1. Introduction

            12.7.3.2. Market Analysis and Forecast by Market Taxonomy

                12.7.3.2.1. By Drug

                12.7.3.2.2. By Modality

                12.7.3.2.3. By Indication

                12.7.3.2.4. By Sales Channel

13. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034

    13.1. Introduction

    13.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023

    13.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2024 to 2034

        13.3.1. By Country

            13.3.1.1. Brazil

            13.3.1.2. Chile

            13.3.1.3. Rest of Latin America

        13.3.2. By Drug

        13.3.3. By Modality

        13.3.4. By Indication

        13.3.5. By Sales Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug

        13.4.3. By Modality

        13.4.4. By Indication

        13.4.5. By Sales Channel

    13.5. Market Trends

    13.6. Drivers & Restraints Impact Analysis

    13.7. Country-Wise Analysis

        13.7.1. Brazil Market Analysis

            13.7.1.1. Introduction

            13.7.1.2. Market Analysis and Forecast by Market Taxonomy

                13.7.1.2.1. By Drug

                13.7.1.2.2. By Modality

                13.7.1.2.3. By Indication

                13.7.1.2.4. By Sales Channel

        13.7.2. Chile Market Analysis

            13.7.2.1. Introduction

            13.7.2.2. Market Analysis and Forecast by Market Taxonomy

                13.7.2.2.1. By Drug

                13.7.2.2.2. By Modality

                13.7.2.2.3. By Indication

                13.7.2.2.4. By Sales Channel

14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034

    14.1. Introduction

    14.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023

    14.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2024 to 2034

            14.3.1.1. By Country

            14.3.1.2. China

            14.3.1.3. Japan

            14.3.1.4. South Korea

        14.3.2. By Drug

        14.3.3. By Modality

        14.3.4. By Indication

        14.3.5. By Sales Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug

        14.4.3. By Modality

        14.4.4. By Indication

        14.4.5. By Sales Channel

    14.5. Market Trends

    14.6. Drivers & Restraints Impact Analysis

    14.7. Country Level Analysis

        14.7.1. China Market Analysis

            14.7.1.1. Introduction

            14.7.1.2. Market Analysis and Forecast by Market Taxonomy

                14.7.1.2.1. By Drug

                14.7.1.2.2. By Modality

                14.7.1.2.3. By Indication

                14.7.1.2.4. By Sales Channel

        14.7.2. Japan Market Analysis

            14.7.2.1. Introduction

            14.7.2.2. Market Analysis and Forecast by Market Taxonomy

                14.7.2.2.1. By Drug

                14.7.2.2.2. By Modality

                14.7.2.2.3. By Indication

                14.7.2.2.4. By Sales Channel

        14.7.3. South Korea Market Analysis

            14.7.3.1. Introduction

            14.7.3.2. Market Analysis and Forecast by Market Taxonomy

                14.7.3.2.1. By Drug

                14.7.3.2.2. By Modality

                14.7.3.2.3. By Indication

                14.7.3.2.4. By Sales Channel

15. South Asia & Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034

    15.1. Introduction

    15.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023

    15.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2024 to 2034

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Thailand

            15.3.1.3. Malaysia

            15.3.1.4. Indonesia

            15.3.1.5. Vietnam

            15.3.1.6. Philippines

            15.3.1.7. Australia & New Zealand

            15.3.1.8. Rest of South Asia & Pacific

        15.3.2. By Drug

        15.3.3. By Modality

        15.3.4. By Indication

        15.3.5. By Sales Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug

        15.4.3. By Modality

        15.4.4. By Indication

        15.4.5. By Sales Channel

    15.5. Market Trends

    15.6. Drivers & Restraints Impact Analysis

    15.7. Country-Wise Analysis

        15.7.1. India Market Analysis

            15.7.1.1. Introduction

            15.7.1.2. Market Analysis and Forecast by Market Taxonomy

                15.7.1.2.1. By Drug

                15.7.1.2.2. By Modality

                15.7.1.2.3. By Indication

                15.7.1.2.4. By Sales Channel

        15.7.2. Thailand Market Analysis

            15.7.2.1. Introduction

            15.7.2.2. Market Analysis and Forecast by Market Taxonomy

                15.7.2.2.1. By Drug

                15.7.2.2.2. By Modality

                15.7.2.2.3. By Indication

                15.7.2.2.4. By Sales Channel

        15.7.3. Malaysia Market Analysis

            15.7.3.1. Introduction

            15.7.3.2. Market Analysis and Forecast by Market Taxonomy

                15.7.3.2.1. By Drug

                15.7.3.2.2. By Modality

                15.7.3.2.3. By Indication

                15.7.3.2.4. By Sales Channel

        15.7.4. Indonesia Market Analysis

            15.7.4.1. Introduction

            15.7.4.2. Market Analysis and Forecast by Market Taxonomy

                15.7.4.2.1. By Drug

                15.7.4.2.2. By Modality

                15.7.4.2.3. By Indication

                15.7.4.2.4. By Sales Channel

        15.7.5. Vietnam Market Analysis

            15.7.5.1. Introduction

            15.7.5.2. Market Analysis and Forecast by Market Taxonomy

                15.7.5.2.1. By Drug

                15.7.5.2.2. By Modality

                15.7.5.2.3. By Indication

                15.7.5.2.4. By Sales Channel

        15.7.6. Philippines Market Analysis

            15.7.6.1. Introduction

            15.7.6.2. Market Analysis and Forecast by Market Taxonomy

                15.7.6.2.1. By Drug

                15.7.6.2.2. By Modality

                15.7.6.2.3. By Indication

                15.7.6.2.4. By Sales Channel

        15.7.7. Australia & New Zealand Market Analysis

            15.7.7.1. Introduction

            15.7.7.2. Market Analysis and Forecast by Market Taxonomy

                15.7.7.2.1. By Drug

                15.7.7.2.2. By Modality

                15.7.7.2.3. By Indication

                15.7.7.2.4. By Sales Channel

16. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034

    16.1. Introduction

    16.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023

    16.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2024 to 2034

        16.3.1. By Country

            16.3.1.1. Germany

            16.3.1.2. Italy

            16.3.1.3. France

            16.3.1.4. United Kingdom

            16.3.1.5. Spain

            16.3.1.6. BENELUX

            16.3.1.7. Nordic Countries

            16.3.1.8. Rest of Western Europe

        16.3.2. By Drug

        16.3.3. By Modality

        16.3.4. By Indication

        16.3.5. By Sales Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug

        16.4.3. By Modality

        16.4.4. By Indication

        16.4.5. By Sales Channel

    16.5. Market Trends

    16.6. Drivers & Restraints Impact Analysis

    16.7. Country-Wise Analysis

        16.7.1. Germany Market Analysis

            16.7.1.1. Introduction

            16.7.1.2. Market Analysis and Forecast by Market Taxonomy

                16.7.1.2.1. By Drug

                16.7.1.2.2. By Modality

                16.7.1.2.3. By Indication

                16.7.1.2.4. By Sales Channel

        16.7.2. Italy Market Analysis

            16.7.2.1. Introduction

            16.7.2.2. Market Analysis and Forecast by Market Taxonomy

                16.7.2.2.1. By Drug

                16.7.2.2.2. By Modality

                16.7.2.2.3. By Indication

                16.7.2.2.4. By Sales Channel

        16.7.3. France Market Analysis

            16.7.3.1. Introduction

            16.7.3.2. Market Analysis and Forecast by Market Taxonomy

                16.7.3.2.1. By Drug

                16.7.3.2.2. By Modality

                16.7.3.2.3. By Indication

                16.7.3.2.4. By Sales Channel

        16.7.4. United Kingdom Market Analysis

            16.7.4.1. Introduction

            16.7.4.2. Market Analysis and Forecast by Market Taxonomy

                16.7.4.2.1. By Drug

                16.7.4.2.2. By Modality

                16.7.4.2.3. By Indication

                16.7.4.2.4. By Sales Channel

        16.7.5. Spain Market Analysis

            16.7.5.1. Introduction

            16.7.5.2. Market Analysis and Forecast by Market Taxonomy

                16.7.5.2.1. By Drug

                16.7.5.2.2. By Modality

                16.7.5.2.3. By Indication

                16.7.5.2.4. By Sales Channel

        16.7.6. BENELUX Market Analysis

            16.7.6.1. Introduction

            16.7.6.2. Market Analysis and Forecast by Market Taxonomy

                16.7.6.2.1. By Drug

                16.7.6.2.2. By Modality

                16.7.6.2.3. By Indication

                16.7.6.2.4. By Sales Channel

        16.7.7. Nordic Countries Market Analysis

            16.7.7.1. Introduction

            16.7.7.2. Market Analysis and Forecast by Market Taxonomy

                16.7.7.2.1. By Drug

                16.7.7.2.2. By Modality

                16.7.7.2.3. By Indication

                16.7.7.2.4. By Sales Channel

17. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034

    17.1. Introduction

    17.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023

    17.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2024 to 2034

        17.3.1. By Country

            17.3.1.1. Russia

            17.3.1.2. Hungary

            17.3.1.3. Poland

            17.3.1.4. Rest of Eastern Europe

        17.3.2. By Drug

        17.3.3. By Modality

        17.3.4. By Indication

        17.3.5. By Sales Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug

        17.4.3. By Modality

        17.4.4. By Indication

        17.4.5. By Sales Channel

    17.5. Market Trends

    17.6. Drivers & Restraints Impact Analysis

    17.7. Country-Wise Analysis

        17.7.1. Russia Market Analysis

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast by Market Taxonomy

                17.7.1.2.1. By Drug

                17.7.1.2.2. By Modality

                17.7.1.2.3. By Indication

                17.7.1.2.4. By Sales Channel

        17.7.2. Hungary Market Analysis

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast by Market Taxonomy

                17.7.2.2.1. By Drug

                17.7.2.2.2. By Modality

                17.7.2.2.3. By Indication

                17.7.2.2.4. By Sales Channel

        17.7.3. Poland Market Analysis

            17.7.3.1. Introduction

            17.7.3.2. Market Analysis and Forecast by Market Taxonomy

                17.7.3.2.1. By Drug

                17.7.3.2.2. By Modality

                17.7.3.2.3. By Indication

                17.7.3.2.4. By Sales Channel

18. Middle East & Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034

    18.1. Introduction

    18.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023

    18.3. Current and Future Market Size (US$ million) and Forecast by Market Taxonomy, 2024 to 2034

        18.3.1. By Country

            18.3.1.1. Saudi Arabia

            18.3.1.2. Türkiye

            18.3.1.3. South Africa

            18.3.1.4. Other African Union

            18.3.1.5. Rest of Middle East & Africa

        18.3.2. By Drug

        18.3.3. By Modality

        18.3.4. By Indication

        18.3.5. By Sales Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug

        18.4.3. By Modality

        18.4.4. By Indication

        18.4.5. By Sales Channel

    18.5. Market Trends

    18.6. Drivers & Restraints Impact Analysis

    18.7. Country Level Analysis

        18.7.1. Saudi Arabia Market Analysis

            18.7.1.1. Introduction

            18.7.1.2. Market Analysis and Forecast by Market Taxonomy

                18.7.1.2.1. By Drug

                18.7.1.2.2. By Modality

                18.7.1.2.3. By Indication

                18.7.1.2.4. By Sales Channel

        18.7.2. Türkiye Market Analysis

            18.7.2.1. Introduction

            18.7.2.2. Market Analysis and Forecast by Market Taxonomy

                18.7.2.2.1. By Drug

                18.7.2.2.2. By Modality

                18.7.2.2.3. By Indication

                18.7.2.2.4. By Sales Channel

        18.7.3. South Africa Market Analysis

            18.7.3.1. Introduction

            18.7.3.2. Market Analysis and Forecast by Market Taxonomy

                18.7.3.2.1. By Drug

                18.7.3.2.2. By Modality

                18.7.3.2.3. By Indication

                18.7.3.2.4. By Sales Channel

        18.7.4. Other African Union Market Analysis

            18.7.4.1. Introduction

            18.7.4.2. Market Analysis and Forecast by Market Taxonomy

                18.7.4.2.1. By Drug

                18.7.4.2.2. By Modality

                18.7.4.2.3. By Indication

                18.7.4.2.4. By Sales Channel

19. Market Structure Analysis

    19.1. Market Share Analysis of Top Players (%)

    19.2. Market Presence Analysis

        19.2.1. Regional footprint of Players

        19.2.2. Drug Type foot print by Players

        19.2.3. Channel Foot Print by Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Branding and Promotional Strategies, By Key Manufactures

    20.3. Key Development Analysis

    20.4. Competition Deep Dive

        20.4.1. Novartis AG

            20.4.1.1. Overview

            20.4.1.2. Product Portfolio

            20.4.1.3. Key Financials

            20.4.1.4. SWOT Analysis

            20.4.1.5. Key Developments

            20.4.1.6. Sales Footprint

            20.4.1.7. Strategy Overview

                20.4.1.7.1. Marketing Strategy

                20.4.1.7.2. Drug Type Strategy

                20.4.1.7.3. Channel Strategy

        20.4.2. Regeneron Pharmaceuticals, Inc. (Sanofi)

        20.4.3. Amgen Inc.

        20.4.4. Innovent Pipeline Companies

        20.4.5. LIB Therapeutics, LLC

        20.4.6. Shanghai Junshi Biosciences Co., Ltd.

        20.4.7. Merck & Co., Inc.

        20.4.8. AstraZeneca

21. Assumptions and Acronyms Used

22. Research Methodology

Recommendations

Healthcare

PARP Inhibitor Market

Published : March 2024

Healthcare

Kinase Inhibitor in Autoimmune Diseases Market

Published : December 2022

Healthcare

Monoclonal Antibodies Market

Published : November 2022

Healthcare

HDL Cholesterol Kits Market

Published : July 2022

Explore Healthcare Insights

View Reports